STERLING WINTHROP KANETTA PHARMACAL MULTISOURCE DIVISION
Executive Summary
STERLING WINTHROP KANETTA PHARMACAL MULTISOURCE DIVISION is launching its first product, a generic injectable version of Wyeth-Ayerst's lorazepam (Ativan). Sterling announced the establishment of the new genetic division April 13, one day after Wyeth lost patent protection for the pre-operative sedative. Sterling received tentative approval for lorazepam injection 2 mg/ml vials and 2 & 4 mg/ml syringe at the end of March ("The Pink Sheet" April 4, T&G-14).